Trial Profile
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Recombinant lactoferrin (Primary)
- Indications Inflammation
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2016 Status changed from recruiting to completed.
- 04 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
- 22 Aug 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.